Oral anticoagulation – current knowlegde

Abstract

Vitamin K antagonists (VKA) and direct oral anticoagulants (DOAC) are two groups of drugs used in the prevention of thromboembolic events. Although DOACs are currently the preferred option in such prophylaxis, there are still indications for the use of VKAs. Thromboembolic episodes may occur as a result of many cardiovascular diseases, inter alia cardiac dysrhythmias. Atrial fibrillation is an arrhythmia that may be asymptomatic or manifested by chest pain, syncope, dyspnea or fatigue. Moreover, it is associated with a high risk of serious complications. An ischemic stroke or myocardial infarction can result from poorly treated AF and may sometimes be the only symptom of an arrhythmia. Therefore, the assessment of a patient's eligibility for anticoagulation therapy is an important element in the prevention of thromboembolic events. Demographic aging and the associated comorbidity may pose a clinical problem in the treatment of atrial fibrillation. The selection of an appropriate anticoagulant therapy should be individualized to the patient's needs.

Keywords

• anticoagulant treatment
• vitamin K antagonists
• direct oral anticoagulants
• atrial fibrillation